BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...EZH2 inhibitor gained accelerated approval for in January, epithelioid sarcoma. FDA also approved Roche’s cobas EZH2...
...equity investment and be eligible for $388 million in milestones, plus royalties. Targets EZH2 - Enhancer of zeste homolog 2...
...Pharmaceutical Inc. Epizyme Inc. Sarepta Therapeutics Inc. Selecta Biosciences Inc. Gelesis Inc. China Medical System Holdings Ltd. Fibroblast growth factor 23 (FGF23) Enhancer of zeste homolog 2 (EZH2)...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...Notch ligand 3 (DLL3) Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Epidermal growth factor receptor variant III (EGFRvIII) Enhancer of zeste homolog 2 (EZH2) Fibroblast...
BioCentury | Jan 23, 2020
Company News

Thirteen years from founding, Epizyme scores first FDA approval

...the first approved therapy to treat epithelioid sarcoma. FDA granted accelerated approval to the first-in-class EZH2...
...classes of epigenetic regulators, when in 2007 it began pursuing inhibitors of histone methyltransferases, including EZH2...
...million. - Staff Writer Elizabeth S. Eaton contributed to this report. Erin McCallister, Senior Editor tazemetostat (E7438, EPZ-6438) Enhancer of zeste homolog 2 (EZH2) Tazverik epithelioid...
BioCentury | Dec 18, 2019
Company News

Dec. 18 Company Quick Takes: FDA approves enfortumab vedotin; plus ODAC roundup, Illumina-PacBio, Benlysta, Ultragenyx, Syros-GBT, Xtandi

...epithelioid sarcoma. Shortly after the vote, Epizyme said it submitted its second NDA for the EZH2...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...epithelioid sarcoma. Luspatercept is a modified activin receptor type 2B (ACVR2B) fusion protein; tazemetostat targets EZH2...
...for Drug Evaluation and Research (CDER). Targets: ACVR2B - Activin receptor type 2B; EZH2 - Enhancer of zeste homolog 2...
BioCentury | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

...Under a 2015 agreement, Eisai paid Epizyme Inc. (NASDAQ:EPZM) royalties on Japanese sales of the EZH2...
...Foundation of America. Jazz’s John Harris and Andrew Firlik joined the board. Targets: EZH2 - Enhancer of zeste homolog 2...
...FRAP; RAFT1) - Mammalian target of rapamycin Hongjiang Li, Staff Writer tazemetostat (E7438, EPZ-6438) Royalty Pharma Eisai Co. Ltd. Epizyme Inc. Enhancer of zeste homolog 2 (EZH2) Mammalian...
BioCentury | Sep 12, 2019
Distillery Therapeutics

Inhibition of G9A and DNMT methyltransferases in bladder cancer

...tumor samples from cisplatin-ineligible bladder cancer patients, expression of G9A, enhancer of zeste homology 2 (EZH2...
...DNMT1) Phosphoinositide 3-kinase catalytic subunit alpha polypeptide (PIK3CA) (p110alpha) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Enhancer of zeste homolog 2 (EZH2) CIEMAT Centro...
BioCentury | Jul 26, 2019
Company News

July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

...is Jan. 23, 2020. Epizyme plans to begin a confirmatory trial this half of the EZH2...
...will own about 4%; the transaction is expected to close this half. Targets: EZH2 - Enhancer of zeste homolog 2...
BioCentury | Jul 18, 2019
Distillery Therapeutics

Inhibiting EZH2 for myeloma-associated bone loss

...EZH2 could help repair myeloma-associated bone loss. Among 20 myeloma patients in remission, levels of EZH2...
...osteolytic bone lesions. In mice in myeloma remission that also exhibited bone loss, knockout of EZH2...
...lymphomas. Pfizer Inc. has the EZH2 inhibitor PF-06821497 in Phase I testing for cancer. TARGET/MARKER/PATHWAY: Enhancer of zeste homolog 2 (EZH2)...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

.../ Eisai Co. Ltd. (Tokyo:4523) Tazemetostat Treat relapsed or refractory follicular lymphoma in patients with EZH2...
Items per page:
1 - 10 of 134